Compare Cognizant Technology Solutions Corp (CTSH) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs Merck & Co., Inc. — how do they compare? Cognizant Technology Solutions Corp trades at $57.66 (market cap $26.40B), while Merck & Co., Inc. trades at $133.65 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 12.2× Cognizant Technology Solutions Corp's market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.
| CTSH | MRK | |
|---|---|---|
Market Cap | $26.40B | $321.77B |
Sector | Technology | Health |
52-Week High | $86.70 | $131.84 |
52-Week Low | $38.73 | $77.60 |
Enterprise Value | $27.44B | $368.53B |
Dividend Yield | 2.25% | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTSH trades at $58.31, up 1.11% today, near its consensus price target of $59.92. The stock shows bullish technical signals with moving averages supporting an uptrend, though oscillators indicate overbought conditions. Recent Q2 2026 earnings missed estimates, but revenue beat expectations, and the company maintains strong profitability with a net margin of 10.26%. AI initiatives and financial services growth are key drivers, as highlighted in recent earnings calls (Seeking Alpha, 2026-07-29).
Outlook: CTSH offers value with a P/E of 12.58 and stable cash flows, but faces risks from client spending caution and competitive pressures. Upside potential exists if AI investments yield growth, though macroeconomic headwinds could limit near-term gains. Analysts are mixed, with 43% recommending buy.
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
